Non-steroidal anti-inflammatory drugs and the chemoprevention of gastrointestinal cancers

Scandinavian Journal of Gastroenterology

Volumn 33, Issue 8, 1998, Pages 785-789

  Vainio, Harri ^a   Morgan, Gareth ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

CHEMOPROPHYLAXIS; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG INDICATION; DRUG MECHANISM; ESOPHAGUS CANCER; HUMAN; PRIORITY JOURNAL; REVIEW; STOMACH CANCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL NEOPLASMS; HUMANS;

EID: 0031668428     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365529850171404     Document Type: Review

References (50)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
3. Morgan GP. Minimising the risks of NSAID pill oesophagitis. Int J Gastroenterol 1996;1:14016.
4. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. Br Med J 1990;300:278-84.
5. Bjarnasson I, Hayllar J, MacPherson AJ, Russell AS. Side-effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-47.
6. Davies NM. Toxicity of non-steroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 1995;38:1311-21.
7. Frolich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase enzymes. TIPS 1997;18:30-4.
8. Bennett A, Del Tacca M. Proceedings: prostaglandins and human colonic cancer. Gut 1975;16:409.
9. Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980;64:1323-7.
10. Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kellof GJ. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992;13: 1019-23.
11. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48:4399-404.
12. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355-8.
13. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the reduced risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
14. IARC handbooks of cancer prevention, Vol 1. Non-steroidal anti-inflammatory drugs. Lyons: International Agency for Research on Cancer. In press.
15. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;157:175-8.
16. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Gastroenterology 1991;101:635-9.
17. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952-4.
18. Giardiello FM, Hamilton SR, Krush AJ, Piantdosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
19. Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial adenomatous polyposis is not prevented by sulindac therapy. Gastroenterology 1994;107:854-7.
20. Lynch HT, Thorson AG, Smyrk T. Rectal cancer after prolonged sulindac chemoprevention: a case report. Cancer 1995;75:936-8.
21. Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, et al. Short communication: sulindac suppresses tumourigenesis in the Min mouse. Carcinogenesis 1996;17:1757-60.
22. Oshima M, Dichuk JE, Kargman S, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyps in APC D761 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
23. Prescott SM, White RL. Self promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 1996;87: 783-6.
24. Arai M, Shimuzi S, Imai Y, Nakatsuru Y, Oda H, Oohara T, et al. Mutations of the Ki-ras, p53 and APC genes in adenocarcinomas of the human small intestine. Int J Cancer 1997;70:390-5.
25. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996;110:1259-62.
26. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression by prostaglandin G/H synthase-1 and -2 protein in human cancer. Cancer Res 1995;55:2556-9.
27. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996;56:4566-9.
28. Takahasi M, Fuktake M, Yokota S, Ishida K, Wakabayashi K, Sugimura T. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclo-oxygenase 2. J Cancer Res Clin Oncol 1996;122:219-22.
29. Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA. Aberrant crypt in human mucosa: putative preneoplastic lesions. J Cell Biochem 1992;Suppl 16G:55-62.
30. Schnitzler M, Dwight T, Robinson BG. Sulindac increases the expression of APC mRNA in malignant colonic epithelial cell lines: an in vitro study. Gut 1996;38:707-13.
31. DuBois RN, Shoa JY, Tsuji M, Sheng HM, Beauchamp RD. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996;56:733-7.
32. Elder DJE, Hague A, Hicks DJ, Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in-vitro transformed adenoma relative to adenoma cell lines. Cancer Res 1996;56:2273-6.
33. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin independent pathway. Biochem Pharmacol 1996;52:237-45.
34. Rubio CA. Antitumoral activity of indomethacin on experimental oesophageal tumours. J Natl Cancer Inst 1984;72:705-7.
35. Shimuzi T. Experimental study of esophageal cancer. Effect of alcohol, vitamin C, prostaglandin E2 and tegafur on the carcinogenesis by N-methyl-N-amyl nitrosamines and the development of esophageal carcinoma. J Jpn Soc Cancer Ther 1986;21:1232-43.
36. Botha JH, Robinson KM, Ramchurren N, Reddi K, Norman RJ. Human esophageal carcinoma cell lines: prostaglandin production, biological properties and behaviour in nude mice. J Natl Cancer Inst 1886;76:1053-6.
37. Funkhouser EM, Sharp GA. Aspirin and the reduced risk of esophageal carcinoma. Cancer 1995;76:1116-9.
38. Morgan GP. Deleterious effects of prostaglandin E2 in oesophageal carcinogenesis. Med Hypoth 1997;48:177-81.
39. Chang-Claude JC, Wahrendorf J, Liang QS, Rei YG, Munoz N, Crespi M, et al. An epidemiological study of precursor lesions of esophageal cancer among young persons in a high-risk population in Hinxian, China. Cancer Res 1990;50:2286-74.
40. Morgan GP, Williams JG. Inflammatory mediators in the oesophagus. Gut 1994;35:297-8.
41. Morgan GP. Deleterious effects of prostaglandin E2 in reflux oesophagitis. Med Hypoth 1996;46:42-4.
42. Zhuang Z, Vortmeyer AO, Mark EJ. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive carcinomas. Cancer Res 1996; 56:1961-4.
43. Fu S, Ramanujam KS, Meitzer SJ, Wilson KT. Expression and localization of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus. Gastroenterology 1997;112: A565.
44. Vaezi MF, Richter JE. Synergism of acid and duodenogastric reflux in complicated Barrett's esophagus. Surgery 1995;117: 699-704.
45. Cauvin JM, Goldfain D, Le Rhun M. Multicentre prospective controlled study of Barrett's oesophagus and colorectal adenomas. Lancet 1995;346:1391-4.
46. Clark GW, Smyrk TC, Burdiles P, Hoeft SF, Peters JH, Kiyabu M, et al. Is Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg 1994;129:609-14.
47. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53: 1322-7.
48. Jalbert G, Castonguay A. Effects of NSAIDs on NNK-induced pulmonary and gastric carcinogenesis in A/J mice. Cancer Lett 1992;66:21-8.
49. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80.
50. van Lieshout EMM, Tiemessen DM, Peters WHM, Jansen JBMJ. Effects of nonsteroidal anti-inflammatory drugs on glutathione S-transterases of the rat digestive tract. Carcinogenesis 1997;18:485-90.